Brief: Karyopharm Receives FDA Fast Track Designation For Selinexor For The Treatment Of Myelofibrosis

Karyopharm Therapeutics

17/07/2023 21:30

July 18 (Reuters) - Karyopharm Therapeutics Inc
 KPTI.O :
    * KARYOPHARM RECEIVES FDA FAST TRACK DESIGNATION FOR
SELINEXOR FOR
THE TREATMENT OF MYELOFIBROSIS
    * KARYOPHARM THERAPEUTICS INC - - PIVOTAL PHASE 3 STUDY OF
SELINEXOR AND RUXOLITINIB IN TREATMENT-NAÏVE MYELOFIBROSIS
INITIATED IN JUNE 2023
    * KARYOPHARM THERAPEUTICS INC - PIVOTAL PHASE 3 STUDY OF
SELINEXOR
AND RUXOLITINIB IN TREATMENT-NAÏVE MYELOFIBROSIS INITIATED IN
JUNE 2023
    * KARYOPHARM THERAPEUTICS INC - TOP-LINE DATA FROM
KARYOPHARM
PHASE 3 STUDY IS EXPECTED IN 2025

Source text for Eikon:  ID:nPn4w8Svsa 
Further company coverage:  KPTI.O 

 (Reuters.Briefs@thomsonreuters.com)